BCDA

BioCardia, Inc.
$1.08previous close on: 9/11/2026

Company Information

Company Name
BioCardia, Inc.
CIK
CIK0000925741
Category
Non-accelerated filer<br>Smaller reporting company
Ticker: Exchange
BCDA: Nasdaq
Fiscal Year End
December 31
Owner Organization
03 Life Sciences
SIC
2836
SIC Description
Biological Products, (No Diagnostic Substances)
Ticker
BCDA

SEC filing data through

Insider Sentiment

Last purchase
2026-06-23
Last sale
2024-12-20
Shares purchased (TTM)
979,793
Shares sold (TTM)
0
Buy ratio (TTM)100.0%

Institutional Sentiment

As of
2026-03-31
Institutional shares owned
666,251
Shares outstanding
10,812,419
Ownership
6.16%
+1.20% Y/Y

Earnings Market Reaction

Filing date
2026-08-12
Price on filing date
1-month reaction
22.73%
3-month reaction
Pending
Drift continued4/11 (36%)
Faded / reversed7/11 (64%)

Balance Sheet

Values in millions ($)
Line item2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-30Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only columnTrend
Assets
Cash And Cash Equivalents At Carrying Value412511251112
Accounts Receivable Net Current000-0-000000
Prepaid Expense And Other Assets Current000000000000
Assets Current413511352112
Property Plant And Equipment Net000000000000
Operating Lease Right Of Use Asset000111111111
Other Assets Noncurrent000000000000
Assets523622463334
Liabilities Current
Accounts Payable Current111111011111
Operating Lease Liability Current000000000000
Contract With Customer Liability Current----------00
Liabilities Current232343234443
Operating Lease Liability Noncurrent000000111111
Liabilities233444345554
Stockholders Equity
Preferred Stock Value000000000000
Common Stock Value000000000000
Additional Paid In Capital175170169169163161161161154152151149
Retained Earnings Accumulated Deficit-172-171-168-166-165-163-160-158-156-154-152-150
Stockholders Equity3-113-2-213-2-2-2-1
Liabilities And Stockholders Equity523622463334
Allowance For Doubtful Accounts Receivable Current000-0-000000
Preferred Stock Par Or Stated Value Per Share0.000.000.000.000.000.000.000.000.000.000.000.00
Preferred Stock Shares Authorized252525252525252525252525
Preferred Stock Shares Issued000000000000
Preferred Stock Shares Outstanding000000000000
Common Stock Par Or Stated Value Per Share0.000.000.000.000.000.000.000.000.000.000.00-
Common Stock Shares Authorized5050505050505050100100100100
Common Stock Shares Issued151111116-552221
Shares Outstanding1511111165552221

Select a line item above to chart it.

Recent filings

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial

BioCardia, Inc. (BCDA) — SEC Financial Statements & Analysis

BioCardia, Inc. (BCDA) is a biological products, (no diagnostic substances) company, incorporated in DE. BioCardia, Inc. trades on Nasdaq as: BCDA. BioCardia, Inc. (BCDA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, BioCardia, Inc. carries a market cap of $15.00M, a P/E ratio of -2.04x, a P/B ratio of 5.55x, a P/S ratio of 3924.95x, an enterprise value of $10.88M, and an EV/EBITDA multiple of -1.47x. On profitability, it posts an operating margin of -281733.33%, a net margin of -279700.00%, a Return on Equity (ROE) of -1803.19%, and a Return on Assets (ROA) of -214.47%. Per share, it reports EPS of $-0.61, diluted EPS of $-0.72, free cash flow per share of $-0.63, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -16.55% year-over-year, and EPS growth of -65.08% year-over-year. On the balance sheet, it maintains a current ratio of 2.09x, a quick ratio of 2.02x, working capital of $2.24M, a debt-to-equity ratio of 0.76x, a debt ratio of 0.43, free cash flow of $-7.57M (TTM), and net debt of $-4.12M. Figures sourced from SEC EDGAR.

Market Cap
$15.00M
P/E TTM
-2.04x
EPS TTM
$-0.61
P/B TTM
5.55x
ROE TTM
-1803.19%
ROA TTM
-214.47%
Debt To Equity
0.76x
Free Cash Flow TTM
$-7.57M
Net Revenue TTM Growth 1Y
-100.00%

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is BioCardia, Inc. in?

BioCardia, Inc. (BCDA) operates in the Biological Products, (No Diagnostic Substances) industry.

What exchange does BCDA trade on?

BioCardia, Inc. (BCDA) trades on the Nasdaq.

Where is BioCardia, Inc. incorporated?

BioCardia, Inc. is incorporated in DE.

When was BioCardia, Inc. (BCDA)'s most recent SEC filing?

BioCardia, Inc. (BCDA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.

What is BCDA's market cap?

BioCardia, Inc. (BCDA) has a market capitalization of $15.00M as of 2026-06-30.

What is BCDA's EPS (earnings per share)?

BioCardia, Inc. (BCDA)'s trailing twelve month EPS is $-0.61 as of 2026-06-30.

What is BCDA's ROE (return on equity)?

BioCardia, Inc. (BCDA)'s trailing twelve month Return on Equity (ROE) is -1803.19% as of 2026-06-30.

What is BCDA's ROA (return on assets)?

BioCardia, Inc. (BCDA)'s trailing twelve month Return on Assets (ROA) is -214.47% as of 2026-06-30.

What is BCDA's EV/EBITDA?

BioCardia, Inc. (BCDA)'s trailing twelve month EV/EBITDA is -1.47x as of 2026-06-30.

Wall Street's data.
Main Street's price.